Aandeel Galapagos

Beleggen en aandelen kopen in België, beursberichten, informatie delen, beurskoersen analyseren + Mid, Small, Fixing
Mikey
Forum gebruiker
Forum gebruiker
Berichten: 110
Lid geworden op: 22 Jul 2016 21:10
waarderingen: 16
Contact:

Re: Aandeel Galapagos

Berichtdoor Mikey » 21 Mei 2019 10:28

Ik wilde terug in gaan stappen. Helaas niet gedaan wanneer ze onder de 100 gingen..



Word gratis lid op Beursig.com

Discussieer met duizenden beleggers en profiteer
van minder advertenties en abonneer op onderwerpen.

Registreer nu binnen enkele tellen



powered by Surfing Waves

Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 585
Lid geworden op: 06 Sep 2018 20:48
waarderingen: 213
Contact:

Re: Aandeel Galapagos

Berichtdoor Naz-T » 21 Mei 2019 10:32

Mikey schreef:Ik wilde terug in gaan stappen. Helaas niet gedaan wanneer ze onder de 100 gingen..

Er is nog niets verloren. Op die paar % die ze nu hoger staan, zal het niet aankomen op de lange termijn. Of je kan nog wachten tot Trump weer een scheet laat om lager in te stappen. Beleggen is soms wat gokken en geluk hebben.
Ik hoop alleszins op een verdere stijging vnaf nu.
Bussie liked last!

Gebruikersavatar
sanderus
Forum elite
Forum elite
Berichten: 3602
Lid geworden op: 07 Aug 2012 08:47
Locatie: Fovea Centralis
waarderingen: 5315
Contact:

Re: Aandeel Galapagos

Berichtdoor sanderus » 21 Mei 2019 12:03

Bridge Biotherapeutics presenteerde resultaten van BBT-887 -ook autotaxin zoals GLPG1690 - voor IPF. Ze stellen BBT-887 als best in class voor.
Er is wel nog wat werk aan de winkel. Fase 1 zou uitgeveord zijn tegen augustus 2019. Fase 2 zou starten ergens begin 2020.
Dus zeker 3 jaar achterstand tov van GLPG1690.


Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea and DALLAS, May 20, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on BBT-877, a drug candidate for treatment of idiopathic pulmonary fibrosis (IPF), at the American Thoracic Society International Conference (ATS 2019) held in Dallas, Texas from May 17-22.

Interim pharmacokinetic and safety results from the randomized, double-blind, placebo-controlled, Phase I study were included in a poster "BBT-877, a potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis" presented on May 19, during the Pathophysiology in Diffuse Parenchymal Lung Diseases poster session.

In the single-ascending dose (SAD) portion of the study, plasma concentrations of BBT-877 increased with dose in a dose-proportional manner. All doses demonstrated safety and tolerability, with only mild adverse events (AEs) and no serious AEs. Furthermore, there were no clinically related findings in safety assessments of the study, such as electrocardiogram, vital sign, laboratory biochemical/hematological profile, and urinalysis results.

"We remain highly focused on the clinical development of BBT-877," said Gwang-hee Lee, PhD, Vice President, Head of Translational Research at Bridge Biotherapeutics. "BBT-877 has shown potential as a best-in-class ATX inhibitor for treatment of IPF with favorable results in the first-in-human, clinical study. These findings reinforce our continued collaborations with world-class pulmonologists specializing in IPF."

The Phase I study of BBT-877 (ClinicalTrials.gov Identifier: NCT03830125) is expected to be finalized by August 2019, and a multinational Phase II study is planned to be conducted in the U.S., Canada, Australia, and multiple countries in Europe and Asia.

Preclinical research of BBT-877 has demonstrated its potency and in vivo efficacy as an ATX inhibitor and best-in-class potential. These interim clinical data contribute to the BBT-877 safety and tolerability demonstrated to date and support the continued development of BBT-877 for treatment of IPF.

http://bridgebiorx.com/upload/pdf/71eba ... 6f2a58.pdf.
jack. liked last!

believer
Forum elite
Forum elite
Berichten: 2979
Lid geworden op: 14 Jan 2015 17:30
waarderingen: 2435
Contact:

Re: Aandeel Galapagos

Berichtdoor believer » 21 Mei 2019 14:19

Evotec,partner van Galapagos neemt Just biotherapeutics over

https://www.fiercebiotech.com/biotech/e ... erapeutics
piddybull liked last!

believer
Forum elite
Forum elite
Berichten: 2979
Lid geworden op: 14 Jan 2015 17:30
waarderingen: 2435
Contact:

Re: Aandeel Galapagos

Berichtdoor believer » 21 Mei 2019 14:22

Evotec jump-starts biologics with acquisition of Just Biotherapeutics

https://www.evotec.com/en

EVOTEC’S OFFERING OF INTEGRATED SOLUTIONS EXTENDED TO BIOLOGICS
ADDITION OF LONGSTANDING BIOLOGICS EXPERTISE BASED ON KEY TALENTS, INNOVATIVE ML (MACHINE LEARNING) DRIVEN TECHNOLOGIES AND SOPHISTICATED PROCESSES
EXPANDING EVOTEC’S US FOOTPRINT IN SEATTLE, A BIOLOGICS HUB
ACCRETIVE TO EVOTEC’S REVENUE GROWTH
CONSIDERATION OF UP TO $ 90 M (APPROX. € 81 M) INCLUDING POTENTIAL EARN-OUTS 2019 – 2022 (E)
TRANSACTION PAID IN CASH
CONFERENCE CALL SCHEDULED FOR TUESDAY, 21 MAY 2019, AT 01.30 PM (CEST) TO INTRODUCE THE TRANSACTION


Hamburg, Germany, 20 May 2019:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years. Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for design, development, and manufacturing of biologics. Founded only in 2014/15, Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA. The acquisition is expected to close in the second quarter 2019.

Opens new growth opportunites as Evotec diversifies into biologics

The acquisition of Just.Bio will add considerable business opportunities for further acceleration of Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation. Evotec’s drug discovery and development value proposition today is to offer the highest quality integrated services mainly in the field of small molecules. The acquisition grows Evotec’s business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Like Evotec in small molecules, Just.Bio is defined by its excellence in science and technology, defined outcomes, smart and highly efficient solutions for developing and manufacturing of biologics at highest standards, thus making an excellent fit.

Just.Bio’s capabilities and expertise comprise an in-house, integrated technology platform, J.DESIGN, enabling smart and efficient biologics’ drug development from design and lead optimisation to manufacturing:

J.MDTM is a technology-based process development tool using Abacus™ as machine learning-based computer-aided design tool to predict and select optimial molecules for further development
JP3® includes lab and computational tools for rapid development of a high-yielding manufacturing process along with a cGMP early clinical manufacturing facility
Significant further potential lies in the company’s J.POD® technology for flexible and modular larger scale manufacturing of clinical and commercial stage biologics
Transaction structure reflects value potential

During recent years, Just.Bio has been able to attract a diversified customer portfolio resulting in strong financial growth. With reported 2018 revenues of approx. € 20 m, Just.Bio was able to achieve revenue growth rates that are above the general market growth. Evotec will pay a total consideration of up to $ 90 m (approx. € 81 m; €/$ fx rate of 1.117) including potential earn outs in the next three years. The initial consideration upon closing is $ 60 m1) (approx. € 54 m; €/$ fx rate of 1.117). The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash to a syndicate of institutional investors of ARCH Venture Partners, Merck & Co., Lilly Asia Ventures and the Bill & Melinda Gates Foundation. The acquisition will add to Evotec’s revenue growth and will strengthen Evotec’s overall strategic plan. The potential guidance update will be given latest upon reporting of half-year 2019 figures. Just.Bio will be financially fully consolidated under the Evotec Group.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: “We are excited about the acquisition and warmly welcome Just.Bio’s expert team as a new part of the Evotec family and also welcome Dr Jim Thomas in his new management role EVP, Global Head, Biotherapeutics, President US Operations. Broadening our platform into biologics has always been key to our strategy. With this acquisition we finally found the perfect match to complement our leadership in small molecules.”

Dr James Thomas, Chief Executive Officer of Just.Bio, commented: “Combining Just.Bio with Evotec creates a technological powerhouse that will fuel our long-term mission to make important biologics accessible to patients worldwide. We are thrilled to be part of the Evotec family.”

1) Subject to customary adjustments for net debt and net working capital



Webcast/Conference Call
Evotec invites you to join a conference call to provide information regarding the acquisition of Just.Bio. The conference will be held in English.

Conference call details

Date: 21 May 2019

Time: 01.30 pm CEST (07.30 am EDT/ 12.30 pm BST)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 0 236 006 663
From the UK: +44 20 3009 2470
From the USA: +1 877 423 0830
Access Code: 75781959#

A simultaneous slide presentation for participants dialling in via phone is available at https://webcasts.eqs.com/evotec20190521/no-audio.

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 2076
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 695
Contact:

Re: Aandeel Galapagos

Berichtdoor neku » 21 Mei 2019 15:18

Naz-T schreef:
Mikey schreef:Ik wilde terug in gaan stappen. Helaas niet gedaan wanneer ze onder de 100 gingen..

Er is nog niets verloren. Op die paar % die ze nu hoger staan, zal het niet aankomen op de lange termijn. Of je kan nog wachten tot Trump weer een scheet laat om lager in te stappen. Beleggen is soms wat gokken en geluk hebben.
Ik hoop alleszins op een verdere stijging vnaf nu.

Er gaan nog scheten van Trump en Xi komen vrees ik, of beter gezegd een ferme lawine...

54770d0b848df5302c66d60b220a8469.jpg
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
Naz-T liked last!
The aim of education is the knowledge, not of facts, but of values!

Gebruikersavatar
sharky
Forum elite
Forum elite
Berichten: 2482
Lid geworden op: 25 Jan 2015 19:47
waarderingen: 770
Contact:

Re: Aandeel Galapagos

Berichtdoor sharky » 21 Mei 2019 18:36

Naz-T schreef:
Mikey schreef:Ik wilde terug in gaan stappen. Helaas niet gedaan wanneer ze onder de 100 gingen..

Er is nog niets verloren. Op die paar % die ze nu hoger staan, zal het niet aankomen op de lange termijn. Of je kan nog wachten tot Trump weer een scheet laat om lager in te stappen. Beleggen is soms wat gokken en geluk hebben.
Ik hoop alleszins op een verdere stijging vnaf nu.

Denk ik ook .Heb vandaag ook nog wat bij gekocht .Gala doet het in huidig klimaat zeker niet slecht en er is rond de 100 veel steun.Had ook eerder gedacht dat die gap ging gesloten worden maar mogelijks blijft dit open nu.Andere biotech schommelt stukken meer momenteel .Er is redelijk wat interesse en dat steunt de koers .De indicatoren zoals rsi ,stochastique neigen opwaarts .
Dus waarom wachten om kopen ?
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
smartie liked last!
Aegon ,KBCA,Galapagos,Pharming,Mithra en nog redelijk wat cash momenteel

believer
Forum elite
Forum elite
Berichten: 2979
Lid geworden op: 14 Jan 2015 17:30
waarderingen: 2435
Contact:

Re: Aandeel Galapagos

Berichtdoor believer » 21 Mei 2019 20:36

https://slimbeleggen.com/kleine-winst-o ... -2/181120/

Galapagos steeg 2,7 procent. Volgens Van Deijck heeft een concurrerend middel een waarschuwing gekregen van toezichthouder EMA, omdat dit niet veilig genoeg zou zijn bij hoge doseringen. De veiligheid is juist het sterke punt van Galapagos’ product filgotinib.
sparrow liked last!

Gebruikersavatar
Lama Daila
Forum veteraan
Forum veteraan
Berichten: 1665
Lid geworden op: 20 Jul 2017 10:53
waarderingen: 2844
Contact:

Re: Aandeel Galapagos

Berichtdoor Lama Daila » 21 Mei 2019 20:49

sanderus schreef:Update clinical trials glpg1690 in IPF.

Momenteel recrutering in 84 locaties. Bijna halfweg in het aantal locaties.

https://clinicaltrials.gov/ct2/results? ... ype=&rslt=

We hadden beiden 2 centers gemist. Het zijn er 86. Ik had er 2 in Duitsland in ISABELA2 vergeten:

B4DBBECF-BD69-4EDA-8AB4-C992CB195677.jpeg
U kunt de afbeeldingen in deze bijlage niet bekijken, registreer hier en bekijk de bijlage.
piddybull liked last!
https://twitter.com/lama_daila

starkeeper
Forum gebruiker
Forum gebruiker
Berichten: 142
Lid geworden op: 28 Aug 2015 15:26
waarderingen: 36
Contact:

Re: Aandeel Galapagos

Berichtdoor starkeeper » 21 Mei 2019 21:15

Zou mij niet verwonderen dat er nog een reuzesprong zich aandient in het laatste half uur.